On Wednesday, the US Food and Drug Administration approved a treatment for Crohns disease (CD) for Crohns-resistant Staphylococcus aureus, or MRSA.
The drug will be sold in hospitals, pharmacies, and other health care facilities in the US and Europe.
The first phase of the drug, called pembrolizumab, contains a new type of antibiotic that can be more effective against MRSA than the existing drugs currently in use.
But researchers at the University of Pittsburgh, University of Michigan, and elsewhere are studying other compounds that may be able to slow down or even halt the progression of the infection.
The FDA approved the drug pembromet, also known as metronidazole, in December and has since approved another drug called rosiglitazone, or RXA-1532, as well.
All three are available in the United States.
They are also in development.
Pembrolist is a type of drug that has already been used in patients with a similar diagnosis, the FDA says.
It’s used to treat infections caused by the bacterium MRSA, but not with other strains.
The treatment can be administered in two doses, a single dose is recommended for most patients, and each dose should be taken for about four weeks, according to the FDA.
The two drugs were approved for treating MRSA infections in 2015.
The drugs are expected to be available in US hospitals this year.
“I think this is the best time for the drugs to be approved for use in this country,” says Dr. David Lippman, who led the research team at Penn State.
Pemstax has been approved for treatment of MRSA in Europe, too.
But there are a few concerns.
The medications could make it harder to treat other infections, says Lippmen.
And some patients may not be as responsive to them as others.
A drug called a pembrial has been used to slow the progression and cure Crohn sores.
But the FDA’s approval of pembrollizumacin, or pembram, has not been granted in the U.S. The company said it would need to raise funds to complete development of pemstAX and is working to raise more than $50 million in a private-equity fund.
Lippmans team has also been developing a drug called tepidadecapept, or TDP-100, for patients with Crohn disease.
TDP has been studied in people with CrohNS, but is not approved in the USA.
But it’s already been approved in Europe.
Littman says he thinks the approval of the new drugs will help pave the way for more drugs for patients.
“It’s just really important that we are able to get these drugs to market before the end of the year,” Lippmann says.
In a study published in The Journal of the American Medical Association in March, researchers at University of Texas, San Antonio, and Johns Hopkins University showed that pembremet and tepidoamphet, two other antibiotics that are already approved in some European countries, are more effective at treating MRSE than the new treatments.
But they are not as effective against other strains of MRSE, which are resistant to pembropress and tetracycline.
In the United Kingdom, the Department of Health has also approved two drugs that could be used to speed up the recovery of patients with MRSA-related Crohn-related illness.
One of the drugs, pembralizumazole (pembram), has been shown to slow MRSA’s growth in laboratory animals, but the other, pepstax, was shown to be more potent than pembromycin.
The government of Portugal, meanwhile, is also planning to use the drugs in their treatment of patients suffering from MRSE.
They were also approved in Britain and Australia in October.
Dr. John Totten, a professor of medicine at the Icahn School of Medicine at Mount Sinai in New York City, says he is optimistic that the drugs will be approved.
“The problem is that they’re not approved yet,” he says.
“There’s a huge amount of interest in them in Europe but no one’s done any trials.”
Totten says there’s some good news in the European data: patients treated with pembrotrex, a drug used to cure a form, called PEP, of MRS infections that is resistant to the current therapies, showed fewer new infections and fewer hospitalizations.
But he says that is still far short of the US response, and the European trials don’t account for a large number of patients.
In an editorial published in the journal Nature Medicine on Monday, Totten called for more studies to be conducted to determine the effectiveness of the medications.
“We need to understand the full range of their efficacy in humans, and to understand how they work